Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Genes that may be involved
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Czech Republic: Betacorton; Estonia: Betacorton; Ireland: Halciderm; Italy: Halciderm; Latvia: Betacorton; Lithuania: Betacorton; Slovakia: Betacorton.

North America

Canada: Halog; USA: Halog.

Latin America

Brazil: Halog; Mexico: Dermalog.


Japan: Adcortin, Mutayain, Sawastin.

Drug combinations

Halcinonide, Neomycin, and Nystatin


Halcinonide: C~24~H~32~ClFO~5~. Mw: 454.96. (1) Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α)-; (2) 21-Chloro-9-fluoro-11β,16α,17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. CAS-3093-35-4 (1973).

Pharmacologic Category

Skin and Mucous Membrane Agents; Anti-inflammatory. Topical Corticosteroid. (ATC-Code: D07AD02).

Mechanism of action

Halcinonide, a synthetic fluorinated corticosteroid, decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.

Therapeutic use

Halcinonide shares actions of the other topical corticosteroids and is used for relief of inflammatory manifestations of corticosteroid-responsive dermatoses.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to halcinonide or any component of the formulation. Viral, fungal, or tubercular skin lesions.

Warnings and precautions

Systemic absorption of topical corticosteroids may cause HPA axis suppression (reversible) particularly in younger children. Allergic contact dermatitis can occur. Prolonged treatment with corticosteroids associated with development of Kaposi’s sarcoma (case reports). Adverse systemic effects including hyperglycemia, glycosuria, fluid and electrolyte changes, and HPA suppression may occur when used on large surface areas, for prolonged periods, or with occlusive dressing. Chronic use of corticosteroids in children may interfere with growth and development. For external use only.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart